Dearborn Partners’s IGC Pharma IGC Stock Holding History

Dearborn Partners’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.2K	Hold	59,401	–	–	﹤0.01%	285
2026 Q1	$15.6K	Sell	59,401 -25,000	-30%	-$6.94K	﹤0.01%	269
2025 Q4	$23.8K	Hold	84,401	–	–	﹤0.01%	264
2025 Q3	$35.2K	Hold	84,401	–	–	﹤0.01%	255
2025 Q2	$25.8K	Hold	84,401	–	–	﹤0.01%	256
2025 Q1	$24.1K	Sell	84,401 -25,000	-23%	-$7.89K	﹤0.01%	257
2024 Q4	$36.8K	Sell	109,401 -7,000	-6%	-$2.62K	﹤0.01%	259
2024 Q3	$49.7K	Hold	116,401	–	–	﹤0.01%	266
2024 Q2	$50.5K	Sell	116,401 -309	-0.3%	-$154	﹤0.01%	255
2024 Q1	$46.7K	Hold	116,710	–	–	﹤0.01%	259
2023 Q4	$32.7K	Hold	116,710	–	–	﹤0.01%	255
2023 Q3	$41.9K	Hold	116,710	–	–	﹤0.01%	235
2023 Q2	$36.4K	Hold	116,710	–	–	﹤0.01%	235
2023 Q1	$39.6K	Sell	116,710 -17,691	-13%	-$6.63K	﹤0.01%	239
2022 Q4	$42.8K	Hold	134,401	–	–	﹤0.01%	243
2022 Q3	$58K	Buy	134,401 +9,375	+7%	+$5K	﹤0.01%	254
2022 Q2	$66K	Buy	125,026 +28,125	+29%	+$17.7K	﹤0.01%	253
2022 Q1	$92K	Hold	96,901	–	–	﹤0.01%	272
2021 Q4	$95K	Hold	96,901	–	–	﹤0.01%	269
2021 Q3	$143K	Hold	96,901	–	–	0.01%	250
2021 Q2	$159K	Hold	96,901	–	–	0.01%	249
2021 Q1	$173K	Hold	96,901	–	–	0.01%	246
2020 Q4	$151K	Hold	96,901	–	–	0.01%	250
2020 Q3	$101K	Sell	96,901 -5,859	-6%	-$5.95K	0.01%	229
2020 Q2	$62K	Hold	102,760	–	–	﹤0.01%	217
2020 Q1	$50K	Hold	102,760	–	–	﹤0.01%	217
2019 Q4	$65K	Hold	102,760	–	–	﹤0.01%	249
2019 Q3	$100K	Hold	102,760	–	–	0.01%	239
2019 Q2	$169K	Hold	102,760	–	–	0.01%	221
2019 Q1	$214K	Buy	102,760 +9,585	+10%	+$21.8K	0.01%	196
2018 Q4	$26K	Buy	+93,175	New	+$476K	﹤0.01%	206

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

Dearborn Partners's IGC Position: Q2 2026 in Review

Dearborn Partners held its IGC Pharma (IGC) position steady in Q2 2026 at 59,401 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #285.

Dearborn Partners first reported a position in IGC in Q4 2018 and has held it in 31 quarters since. The position peaked at $214K in Q1 2019. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

Dearborn Partners held 59,401 shares of IGC Pharma worth $16.2K as of Q2 2026.
Dearborn Partners left its IGC Pharma share count unchanged in Q2 2026.
IGC Pharma made up ﹤0.01% of Dearborn Partners's portfolio in Q2 2026, its #285 holding.
Dearborn Partners first reported a position in IGC Pharma in Q4 2018 and has held it in 31 quarters since.
Dearborn Partners's IGC Pharma position peaked at $214K in Q1 2019.
36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on Dearborn Partners's 13F filing for Q2 2026, filed 13 Aug 2026.